Dr. Moon J. Noh has been with Kolon TissueGene for over 16 years. Prior to his role here, Dr. Noh was the Director of the Biotechnology Lab at Kolon Central Research Park. Dr. Noh holds a Ph.D. and M.S. from the Korea Advanced Institute of Science and Technology in Molecular Biology.

Dr. Seng-Ho Jeon holds a Ph.D. in Pharmaceutical Sciences from Yonsei University, an MBA from Aalto University School of Business, a Master’s degree in Pharmaceutical Sciences from Seoul National University, and a Bachelor’s degree in Pharmacy from Seoul National University.

He served as CEO and President of Daewoong Pharmaceutical from 2018 to 2024, where he led the company’s growth and global expansion. He also held concurrent leadership roles, including CEO of Affycell Therapeutics (2020 to April 2024) and CEO of Daewoong Investment (2023 to April 2024). In addition, he has been serving as a board member of Korea Science & Technology Holdings since 2023, and as an advisor and board member at the Future Medicine Research Foundation since 2021.

Jung In Kim joined Kolon TissueGene, Inc. in December, 2021 as the Chief Financial Officer and the Korea Branch leader. Before she joined Kolon TissueGene, she served as a director of the Management and Finance division in Kolon Corporation. She received his Bachelor of Arts in Mathematics at Kookmin University in Korea and acquired her CPA license from Korea Institute of Certified Public Accountant.

In addition to his roles as the Outside Director at Kolon TissueGene, SunJoo Lee also serves as the Professor in Gynecologic Oncology, Konkuk University School of Medicine. He received his Ph. D. degree from Chung-Ang University, School of Medicine, Pharmacology and M.D. degree from Seoul National University, School of Medicine, Seoul, Korea.

Young J. Kim’s founded and successfully led companies in the U.S. commercial and government service industries for many years. He received his Doctorate in Engineering Management at George Washington University.